Latest Probiotics News

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Terragen Holdings secures a landmark supply agreement for its probiotic and biostimulant products with Ravensworth Feedlot, alongside a $2.8 million funded trial at Mort & Co’s Grassdale feedlot to validate its probiotic’s impact on cattle performance.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Terragen Holdings’ biostimulant Great Land Plus® has been independently shown to increase maize silage yields by up to 12%, translating into an estimated $1,100 additional revenue per hectare and a potential 20-fold return on investment.

Biome Australia Limited has reported a robust half-year performance, with revenues climbing nearly 40% and net profit more than doubling, driven by strong product momentum and strategic investments.

Terragen Holdings reports a 23% reduction in half-year net loss amid strategic shifts and completes a $7 million equity raise to accelerate global commercialisation of its biological agricultural products.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.